Eupraxia Pharmaceuticals (EPRX) AI Stock Analysis

• Market Cap: C$201.72M
• Dividend Yield: N/A
• Average Volume (3M): 38.55K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.01
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: CA
• Employees: 33
• Sector: Healthcare
• Sector Strength: 53
• Industry: Biotechnology
• EPS (TTM): -0.26
• Shares Outstanding: 35,849,354
• 10 Day Avg. Volume: 55,673
• 30 Day Avg. Volume: 38,551
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• Price to Cash Flow (P/CF): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: C$16.54
• Price Target Upside: 198.56% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

Eupraxia Pharmaceuticals' overall score reflects its challenging financial position with no revenue and ongoing net losses. While recent positive trial results and operational progress are encouraging, the company's reliance on external financing and high liabilities pose significant risks. Technical indicators suggest some positive momentum, but valuation challenges persist due to lack of profitability. The strengthened financial position through capital raise is a mitigating factor but does not offset the underlying financial instability.

Eupraxia Pharmaceuticals Business Overview & Revenue Model

Company Description

Eupraxia Pharmaceuticals (EPRX) is a clinical-stage biotechnology company focused on developing innovative drug products for the treatment of chronic diseases. The company's primary focus is on creating long-acting formulations that aim to provide sustained therapeutic effects, particularly in areas with significant unmet medical needs such as osteoarthritis and other pain-related conditions. Eupraxia's lead product candidate is EP-104IAR, a proprietary sustained-release formulation intended to alleviate pain and improve joint function in patients with osteoarthritis.

How the Company Makes Money

Eupraxia Pharmaceuticals primarily generates revenue through the development and potential commercialization of its drug candidates. The company is focused on advancing its lead product candidates through clinical trials, seeking regulatory approval, and ultimately bringing these products to market. Revenue is expected to be derived from product sales, licensing agreements, and strategic partnerships. Eupraxia may engage in collaborations with larger pharmaceutical companies to co-develop or commercialize its products, thus gaining access to additional resources and market channels. However, as a clinical-stage company, Eupraxia's current revenue is likely limited and largely dependent on funding from investors, grants, or milestone payments from partnerships until its products receive regulatory approval and can be commercialized.

Eupraxia Pharmaceuticals Financial Statement Overview

Summary

Eupraxia Pharmaceuticals is in a growth phase, with initial revenue generation marking a positive step. However, profitability and liquidity issues, coupled with a historically high debt load, present significant challenges. Continued focus on revenue growth and cost management will be vital for future financial health.

Income Statement

Eupraxia Pharmaceuticals has shown a significant improvement in revenue with a TTM figure of $2.98 million, up from zero in previous years, indicating a positive growth trajectory. However, the company is still operating at a substantial loss, with negative net income, EBIT, and EBITDA margins, reflecting ongoing challenges in achieving profitability.

Balance Sheet

The company's debt-to-equity ratio has improved as stockholders' equity turned positive in the recent TTM period. However, the equity ratio is low, and the high historical liabilities indicate potential risk. The improvement in stockholders' equity and reduction in total liabilities are positive signs, but overall financial stability remains a challenge.

Cash Flow

Negative operating and free cash flows highlight liquidity challenges. However, there is an improvement in free cash flow over time, reducing from previous periods. The company has managed financing activities effectively to support cash flow needs, yet the reliance on external financing poses a risk.

Breakdown
Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement		Total Revenue
0.00	0.00	0.00	0.00	0.00
	Gross Profit
-209.91K	-193.27K	-111.53K	-116.81K	-201.94K
	EBIT
-36.90M	-22.63M	-20.87M	-2.25M	-6.15M
	EBITDA
-37.40M	-22.14M	-21.96M	-2.01M	-5.94M
	Net Income Common Stockholders
-37.39M	-23.26M	-22.99M	-4.00M	-7.18M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
19.34M	24.74M	29.90M	150.13K	1.16M
	Total Assets
26.72M	25.88M	31.22M	1.45M	3.29M
	Total Debt
10.45M	10.55M	9.56M	12.77M	11.94M
	Net Debt
-11.72M	-14.19M	-11.34M	12.62M	10.78M
	Total Liabilities
25.55M	14.51M	11.67M	23.12M	21.42M
	Stockholders Equity
2.22M	12.86M	20.39M	-21.21M	-17.69M
Cash Flow		Free Cash Flow
-28.02M	-19.08M	-15.07M	-403.93K	-5.18M
	Operating Cash Flow
-27.92M	-18.78M	-14.64M	-403.93K	-5.17M
	Investing Cash Flow
-99.03K	8.70M	-14.45M	24.62K	-1.90M
	Financing Cash Flow
27.84M	13.52M	49.92M	-626.64K	7.40M

Eupraxia Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.54
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:EPRX, the sentiment is Positive. The current price of 5.54 is above the 20-day moving average (MA) of 5.04, above the 50-day MA of 5.18, and above the 200-day MA of 4.34, indicating a bullish trend. The MACD of 0.18 indicates Negative momentum. The RSI at 55.17 is Neutral, neither overbought nor oversold. The STOCH value of 26.05 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TSE:EPRX.

Eupraxia Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GUD	66 Neutral	$605.64M	138.41	0.53%	―	13.13%	―
CRON	62 Neutral	$971.26M	16.98	3.80%	―	35.87%	―
BHC	54 Neutral	$2.42B	―	3.60%	―	11.87%	91.09%
Sector *	52 Neutral	$5.23B	3.70	-41.86%	2.84%	16.58%	-0.16%
EPRX	45 Neutral	C$201.72M	―	-108.05%	―	―	―
ONC	43 Neutral	$60.50M	―	-184.69%	―	―	0.10%

Eupraxia Pharmaceuticals Corporate Events

Eupraxia Pharmaceuticals Reports Strong Q4 2024 Results and Operational Progress

Eupraxia Pharmaceuticals announced its fourth quarter 2024 financial results, highlighting significant advancements in its RESOLVE trial for eosinophilic esophagitis and a strengthened financial position with a C$44.5 million capital raise. The company reported a reduced net loss due to lower research and development costs and increased cash reserves, positioning it well for continued operations into 2026. Key operational updates included leadership changes and positive trial data, which may enhance its industry standing and stakeholder confidence.

Eupraxia Pharmaceuticals Reports Promising Trial Results for Eosinophilic Esophagitis Treatment

Eupraxia Pharmaceuticals has announced positive results from its RESOLVE Phase 1b/2a trial for EP-104GI, a treatment for eosinophilic esophagitis. The trial showed significant improvements in symptom relief and tissue health, particularly in Cohort 6, with no serious adverse events reported. The data suggests that higher doses and increased esophageal coverage of EP-104GI lead to better outcomes, encouraging further exploration of its potential benefits.